Highest-materiality recent filing
USPH acquires 67% stake in 12-clinic PT practice; adds 45th state
USPH acquired a 67% equity interest; 33% retained by current owners.
USPH shareholders elect directors, approve say-on-pay and auditor at annual meeting
Seven directors elected with large majorities; highest vote for Peter F. Minan (14,005,301 for, 102,931 withheld).
USPH discusses Q1 2026 results on conference call; no specific financials in filing
Conference call held May 7, 2026 to review Q1 2026 results.
USPH Q1 revenue $198.3M (+7.9% YoY); GAAP loss $0.12/share, adjusted EBITDA rises to $20.2M
Revenue $198.3M, up 7.9% YoY; GAAP net income $5.0M, loss per share $0.12 vs EPS $0.80 prior year.
USPH enters $450M credit facility with $275M revolver and $175M term loan, maturing 2031
New $450M credit facility comprises $275M revolver and $175M term loan, matures April 14, 2031.
USPH sets 2026 executive comp plans with EBITDA targets for RSUs and bonuses
CEO target 12,752 RSUs; 2026 Adj. EBITDA target $105.6M; max 150% at $108.24M.
USPH files updated investor presentation; no financial details in filing
Investor presentation updated on March 6, 2026, available on company website.
Conference call transcript for Q4 and full year 2025 results was furnished as Exhibit 99.1.
USPH reports FY2025 Adj. EBITDA $95M (+16%); CFO resigns; dividend raised to $0.46
FY2025 net revenue $781M (+16.3% YoY); Adj. EBITDA $95M (+16.2%); GAAP EPS $1.42 vs $1.84 prior.
Acquired 70% of industrial injury prevention business for ~$15.1M; target generates ~$7M in annual revenue.
USPH acquires 50% stake in 8-clinic PT management firm with $8M revenue
Acquired 50% interest in a physical therapy management company managing eight clinics.
U.S. Physical Therapy updates investor presentation on November 18, 2025
Presentation covers company overview and is posted on USPH.com under Investor Relations.
USPH files Q3 2025 earnings call transcript but no specific results available in excerpt
Conference call held Nov 6, 2025 to discuss Q3 2025 results; transcript furnished as Exhibit 99.1.
US Physical Therapy Q3 revenue up 17.8% to $168.1M; EPS $0.48; reaffirms FY2025 guidance
Revenue $168.1M (+17.8% YoY); USPH Net Income $13.1M ($0.48 EPS) vs $6.6M ($0.39 EPS) prior year.
USPH updates investor presentation for Q2 2025; no specific data disclosed in filing
Company posted updated investor presentation on its website under IR section.
USPH furnishes Q2 2025 earnings call transcript; results not in filing excerpt
Filed under Item 7.01 Regulation FD; transcript of August 7, 2025 conference call is provided.
US Physical Therapy Q2 net income $12.4M; raises FY Adj EBITDA guidance to $93M-$97M
Q2 total revenue from PT ops $168.3M (+17.3%), IIP revenue $29.1M (+22.6%); record patient visits 1.56M (+16.7%).
USPH acquires 60% stake in 3-clinic PT practice with $5.3M revenue
Acquired 60% ownership in a physical therapy practice operating three clinic locations.
USPH furnishes Barrington research report via Reg FD; no new material info
Barrington Research circulated a report on July 1, 2025, based on conversations with USPH management.
U.S. Physical Therapy dual lists common stock on NYSE Texas as Founding Member
Dual listing announced May 28, 2025; maintains primary NYSE listing with same USPH ticker.
US Physical Therapy shareholders elect all eight director nominees at annual meeting
All eight director nominees elected; highest votes for Nancy J. Ham (13,500,869), lowest for Dr. Bernard A. Harris, Jr. (12,422,647).
Company hosted a conference call on May 8, 2025 to discuss Q1 2025 results.
Company furnished an updated investor presentation as Exhibit 99.1 on May 12, 2025.
USPH Q1 net income $9.9M ($0.80 EPS); revenue up 16.4% to $183.8M
Net income $9.9M ($0.80 EPS) vs $8.0M ($0.46) in Q1 2024.
U.S. Physical Therapy subsidiary acquires 80% of home care practice with $2.1M revenue
50%-owned subsidiary MSO Metro, LLC acquired 80% interest in an outpatient home care practice.
Compensation Committee approved four executive incentive plans for 2025, effective March 26, 2025.
U.S. Physical Therapy updates investor presentation on website; no new financial details disclosed
Company posted an updated investor presentation on its website on March 7, 2025.
USPH acquires 65% stake in Wyoming therapy practice generating $4.3M revenue
Acquired practice has three clinic locations in Wyoming with $4.3M annual revenue and 23,000 visits.
USPH Q4 revenue up 14.2% to $180.4M; adjusted EBITDA $21.8M; dividend raised to $0.45
Q4 net revenue $180.4M (PT $153.8M + IIP $26.6M), vs $154.8M prior year; full-year revenue $671.3M.
Acquired 75% interest in a hand and physical therapy practice with 8 clinic locations in Wyoming.
USPH CEO and CFO to present at two investor conferences on Nov 20, 2024
CEO Chris Reading to participate in Stephens Annual Investment Conference on November 20, 2024.
U.S. Physical Therapy provides Q3 2024 earnings call transcript; no financial specifics in excerpt
Conference call held Nov 6, 2024 to discuss Q3 and nine months ended Sept 30, 2024.
USPH Q3: Adjusted EPS $0.55, record visits, IIP revenue up 30%, two acquisitions
Q3 GAAP EPS $0.39 (net income $6.6M); adjusted EPS $0.55 excluding $2.5M (net) clinic closure costs.
USPH closes $76.5M acquisition of 50% interest in Metro, 50-clinic operator
Paid ~$76.5M: $75M cash plus 18,358 shares of USPH common stock.
U.S. Physical Therapy acquires 50% stake in 50-clinic MSO for $76.5M
Purchase price $76.5M ($75M cash + $1.5M in USPH stock); sellers can earn up to $20M additional earnout based on performance.
US Physical Therapy acquires 70% stake in 8-clinic PA practice with $5.5M revenue
Acquired 70% interest in a Pennsylvania physical and hand therapy practice.
USPH CEO to present at Midwest IDEAS Investor Conference on Aug 28, 2024
Chris Reading, Chairman and CEO, will present at the 15th Annual Midwest IDEAS Investor Conference.
USPH furnishes Q2 2024 conference call transcript and investor presentation
Filed under Item 7.01 Regulation FD; transcript of August 14 call discussing Q2 2024 results.
USPH Q2 revenue up 8.5% to $143.5M; EPS $0.47 vs $0.64; guidance reaffirmed at $80-85M EBITDA
GAAP net income $7.5M ($0.47 diluted EPS) vs $10.9M ($0.64) in Q2 2023; share count up from May 2023 secondary offering.
USPH CEO to present at CJS Securities New Ideas Conference on July 10
CEO Chris Reading will present at the CJS Securities 24th Annual New Ideas Summer Conference on Wed, July 10, 2024.
CEO Chris Reading to present at East Coast IDEAS Conference on June 12, 2024
Chris Reading, CEO, will present at the 14th Annual East Coast IDEAS Conference 2024.
USPH amends executive severance to add pro rata incentive awards for five officers
Amended employment agreements for CEO Reading, President Williams, COO Reeve, CFO Hendrickson, GC Binstein.
USPH CFO to present at Jefferies Global Healthcare Conference on June 5, 2024
CFO Carey Hendrickson will present at the Jefferies Global Healthcare Conference on June 5, 2024.
U.S. Physical Therapy appoints CEO Reading as Chairman, promotes Williams to President
Christopher Reading, CEO since 2004, named Chairman effective May 21; replaces Edward Kuntz (retired).
USPH holds Q1 2024 earnings call; Eric Williams named President
Q1 2024 financial results discussed on May 8 call; specific figures not in this exhibit.
USPH CEO and CFO to present at Bank of America Healthcare Conference on May 14
Chris Reading (CEO) and Carey Hendrickson (CFO) will present at the Bank of America Securities Healthcare Conference 2024.
US Physical Therapy Q1 revenue up 4.1%, EPS $0.46; raises FY 2024 EBITDA guidance to $82.5M-$87.5M
Q1 2024 net income $8.0M ($0.46 EPS) vs $7.4M ($0.58 EPS) in prior year; adjusted EBITDA $16.7M.
USPH re-appoints Compensation Committee; Swanson steps down over independence feedback
Board re-appointed Compensation Committee: Kathleen Gilmartin (Chair), Anne Motsenbocker, Edward Kuntz.
U.S. Physical Therapy clarifies director independence for Regg Swanson's re-election
Regg Swanson nominated for re-election as director at May 21, 2024 annual meeting.
U.S. Physical Therapy buys IIP business for ~$24M and a two-clinic PT practice
Briotix subsidiary acquired an IIP services business for ~$24.0M; annual revenue ~$11.0M.
In connection with the transactions contemplated by the Purchase Agreement, and effective as of February 24, 2025, the Company expanded its board of directors (the “Board”) from seven to eight directors and appointed Michael G. Mayrsohn as a director of the Company to fill such vacancy.
Mr. Reading replaces Edward L. Kuntz, who retired as the Chairman of the Company’s Board of Directors as of the Annual Meeting.
the Board of Directors of the Company appointed Mr. Christopher J. Reading, the Company’s Chief Executive Officer since 2004 and a member of the Board of Directors, to also serve as Chairman of the Board of Directors.
In addition, Dr. Bernard Harris will now serve as the Lead Independent Director on the Board of Directors.
The Company has also promoted Eric Williams to the office of President effective as of the completion of the Annual Meeting.
on May 16, 2023, Ms. Nancy Ham was elected to serve on board of directors (the “Board”) of U.S. Physical Therapy, Inc. (the “Company”) (NYSE: USPH)
Effective April 28, 2022, Jake J. Martinez, age 43, joined U. S. Physical Therapy, Inc. as Senior Vice President/Finance and Accounting.
On March 17, 2022, Rick Binstein, was appointed as an Executive Vice President of the Company.
U.S. Physical Therapy, Inc. ("USPH" or the “Company”) (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced that its Board of Directors, upon recommendation of its Nominating Committee, has appointed Anne Motsenbocker, age 60, to serve on the Board, effective January 1, 2022.
Mr. McDowell will retire from his position as Chief Operating Officer – West effective August 31, 2021.
Max materiality 0.80 · Median 0.35 · Most common event other_material